MaxCyte CEO Says FDA OK Of IND For Its CAR Receptor Candidate Major Milestone

 
• By Sten Stovall
CART
IND Means First CARMA Trial Is On Track For Dosing In Second Half 2018 • Source: Shutterstock

More from Clinical Trials

More from R&D